- Home
- CHRS vs EXFY Comparison
CHRS vs EXFY Comparison
Compare CHRS & EXFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- EXFY
- Stock Information
- Founded
- CHRS 2010
- EXFY 2008
- Country
- CHRS United States
- EXFY United States
- Employees
- CHRS N/A
- EXFY N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- EXFY Computer Software: Prepackaged Software
- Sector
- CHRS Health Care
- EXFY Technology
- Exchange
- CHRS Nasdaq
- EXFY Nasdaq
- Market Cap
- CHRS 194.1M
- EXFY 165.4M
- IPO Year
- CHRS 2014
- EXFY 2021
- Fundamental
- Price
- CHRS $1.70
- EXFY $1.59
- Analyst Decision
- CHRS Strong Buy
- EXFY Strong Buy
- Analyst Count
- CHRS 4
- EXFY 3
- Target Price
- CHRS $4.51
- EXFY $4.75
- AVG Volume (30 Days)
- CHRS 1.0M
- EXFY 412.3K
- Earning Date
- CHRS 11-07-2025
- EXFY 11-06-2025
- Dividend Yield
- CHRS N/A
- EXFY N/A
- EPS Growth
- CHRS N/A
- EXFY N/A
- EPS
- CHRS 1.55
- EXFY N/A
- Revenue
- CHRS $272,209,000.00
- EXFY $144,251,000.00
- Revenue This Year
- CHRS N/A
- EXFY $5.45
- Revenue Next Year
- CHRS $109.48
- EXFY $2.56
- P/E Ratio
- CHRS $3.38
- EXFY N/A
- Revenue Growth
- CHRS 52.33
- EXFY 4.13
- 52 Week Low
- CHRS $0.66
- EXFY $1.60
- 52 Week High
- CHRS $2.43
- EXFY $4.13
- Technical
- Relative Strength Index (RSI)
- CHRS 54.43
- EXFY 34.37
- Support Level
- CHRS $1.64
- EXFY $1.63
- Resistance Level
- CHRS $1.81
- EXFY $1.76
- Average True Range (ATR)
- CHRS 0.10
- EXFY 0.06
- MACD
- CHRS -0.02
- EXFY 0.00
- Stochastic Oscillator
- CHRS 42.32
- EXFY 5.56
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.